Julio Delgado

Has grant

Head

Hospital Clínic de Barcelona

Spain

Research Interests

Explore related searches

Professors in Spain Professors in Immunology Immunology professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Julio Delgado is the Head at Hospital Clínic de Barcelona, Spain. His research focuses on CAR T-cell therapies and their implications for hematologic malignancies. Recent studies include investigations into the efficacy and safety of CAR T-cell products, patient-reported outcomes, and the role of microbiota in therapy responses.

Recent Grants

Grant: Open

First-in-human, open-label, prospective, non-randomized clinical trial to evaluate the safety of ARI-HER2 (HER2BBz CAR-T cells) in subjects with relapsed or refractory HER2-positive metastatic breast cancer.

Open Date: 2024-01-01

Close Date: 2026-12-01

Grant: Close

CARTD-BG-01: Ensayo fase I, piloto, abierto, multicéntrico, no aleatorizado para evaluar la seguridad y eficacia de las células ARI-0003 (CART19/269) en pacientes con linfoma B agresivo recaído/refractario

Open Date: 2023-01-01

Close Date: 2025-12-01

Grant: Close

Implementación de la producción escalada y centralizada de vectores virales para manufactura de varnimcabtagene autoleucel (var-cel) para su desarrollo comercial y expansión internacional (INVECTO)

Open Date: 2023-01-01

Close Date: 2024-12-01

Grant: Close

CART19-BE-02: Phase II clinical trial on the use of ARI-0001 cells in patients with CD19+ relapsed/refractory acute lymphoid leukemia

Open Date: 2019-01-01

Close Date: 2021-12-01

Grant: Close

Desarrollo de mejoras de la eficacia en nuestra propuesta académica de CART19 para síndrome linfoproliferativos B: modificaciones imprescindibles para mejorar resultados

Open Date: 2019-01-01

Close Date: 2021-12-01

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (6)

Laura Hilton

Adjunct Professor

Simon Fraser University

CANADA

View details

Jesús María Hernández-Rivas

Universidad de Salamanca

SPAIN

View details

Jordan Gauthier

Assistant Professor

Fred Hutchinson Cancer Research Center

UNITED STATES

View details

Lorena Pérez Amill

Glyscend Therapeutics

SPAIN

View details

MARIA VELASCO DE ANDRES

SPAIN

View details

Andrea Visentin

Assistant professor

University of Padua

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Julio Delgado

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (20)

CD6 expression is an independent predictor of time to first treatment in chronic lymphocytic leukemia.

CD19 CAR T‐Cell Therapy for Primary Mediastinal Large B‐Cell Lymphoma: A CIBMTR Analysis

ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker

Disease-specific U1 spliceosomal RNA mutations in mature B-cell neoplasms

Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe.

Efficacy and safety of the academic anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel for the treatment of relapsed/refractory follicular lymphoma.

Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma.

T-cell responses against CD19-targeted CAR T cells varnimcabtagene autoleucel (ARI-0001): implications for immune response and therapy outcomes

A novel chimeric antigen receptor T-cell therapy targeting CD84 for the treatment of acute myeloid and T-cell lymphoblastic leukemias.

Implementation of a quality management system for decentralized manufacturing of cell and gene therapy products - technical and regulatory considerations.

Chimeric Antigen Receptor T-Cell Postinfusion Fever: Infection Profile, Clinical Parameters, and Biomarkers Trends to Assist Antibiotic Stewardship

InsT‐ALLing CD7 chimeric antigen receptors before transplantation

The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B‐cell malignancies

Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation

Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation

A low total metabolic tumor volume independently predicts for a longer time to first treatment in initially observed, low tumor burden follicular lymphoma

Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC)

Infection epidemiology in relation to different therapy phases in patients with haematological malignancies receiving CAR T-cell therapy

Integrative single-cell multi-omics of CD19CARpos and CARneg T cells suggest drivers of immunotherapy response in B-cell neoplasias

Collaborators (6)

Laura Hilton

Jesús María Hernández-Rivas

Jordan Gauthier

Lorena Pérez Amill

MARIA VELASCO DE ANDRES

Andrea Visentin

Make your next move.